As evidenced in different ovarian cancer cell lines and as noted before also in human tissue samples mTOR pathway activation is not an ubiquitous finding in ovarian cancer drug resistance, hence stratification via a biomarker is necessary. Here, MTOR is linked to ovarian carcinoma.